Venture&Growth
Location
San Jose (CA), USA
Since: 2019
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
US-based MedTech focused on treatment of hypertension via renal denervation.
Ablative Solutions is a medical device company that has developed a best-in-class drug delivery catheter, the Peregrine SystemTM, which delivers a neurolytic agent to the adventitia of the renal arteries for the purposes of ablating the surrounding nerves.
This procedure, known as renal denervation, has a potentially significant effect in the treatment of hypertension.
The Ablative Solutions procedure is quick, relatively painless and results in deep, circumferential ablation of the renal nerves.
The company has CE Mark and is currently engaged in clinical studies in Europe and the United States.
More Ablative Solutions news
Gilde Healthcare’s Ablative Solutions, Inc. meets Primary Endpoint in Pivotal Trial for Hypertension
Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions
Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension
Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer
Venture&Growth
Spyglass Pharma
Spyglass Pharma was founded in 2019 and is based in Aliso Viejo, California. They are developing a drug delivery platform mounted on an intraocular lens to address mild-moderate glaucoma in patients undergoing cataract surgery. The lead asset utilizes a well-established
Venture&Growth
Tagworks
Tagworks Pharmaceuticals is a privately held therapeutics company based in the Netherlands. It leverages unique technologies to increase efficacy and decrease toxicity across multiple systemic treatment modalities. The company has pioneered a unique and proprietary Click-to-Release drug development technology, enabling
Venture&Growth
SynOx Therapeutics
SynOx Therapeutics Limited is a Dublin-based, late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders. TGCT is a rare, non-malignant but
